Financial data from the second quarter shows CX Institutional boosting its holdings in Amphastar Pharmaceuticals by 220.5%. This move involves the purchase of more than 180,000 additional shares, totaling a $6.05 million investment in the NASDAQ-listed firm.
CX Institutional Has $6.05 Million Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

Key Takeaways:
- CX Institutional’s holdings in Amphastar Pharmaceuticals increased by 220.5% in Q2
- An additional 181,136 shares were purchased
- The total number of shares is now 263,283
- The total value of these holdings stands at $6,045,000
- All investment data comes from Holdings Channel reports
CX Institutional’s Investment Surge
In a noteworthy financial disclosure for the second quarter, CX Institutional raised its holdings in Amphastar Pharmaceuticals by an impressive 220.5%. This move signaled a considerable vote of confidence in the NASDAQ-listed company, known by its ticker symbol AMPH.
Share Count and Valuation
Before this acquisition, CX Institutional held fewer shares in Amphastar. Upon purchasing an additional 181,136 shares, its total stake rose to 263,283 shares. According to filings, the value of these holdings stands at $6,045,000, demonstrating the institution’s substantial commitment to Amphastar.
Further Details from Holdings Channel
Reported by Holdings Channel, the purchase sheds light on CX Institutional’s objectives during the second quarter. The added shares underline the institution’s decision to significantly broaden its position within Amphastar Pharmaceuticals.
Implications for Amphastar
While the exact motivations behind CX Institutional’s increased stake were not disclosed, such a marked escalation in share ownership often points to confidence in the underlying fundamentals or future performance of the company. Investors and market observers alike will be monitoring Amphastar’s outlook in the wake of this development.